What is Arcutis Biotherapeutics, Inc.'s R&D?

Arcutis Biotherapeutics, Inc. (ARQT) reported R&D of $30.63M in Q1 2026.

How has Arcutis Biotherapeutics, Inc.'s R&D changed year-over-year?

Arcutis Biotherapeutics, Inc.'s R&D increased by 74.6% year-over-year, from $17.54M to $30.63M.

What is the long-term trend for Arcutis Biotherapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s R&D has grown at a -14.7% compound annual growth rate (CAGR), from $145.56M to $77.05M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Arcutis Biotherapeutics, Inc. ARQT R&D

R&D at other companies

AmgenAMGN

$1.72B+15.7%

IncyteINCY

$515.9M+18.0%

OrganonOGN

$93M-3.1%

Kymera TherapeuticsKYMR

$98.16M+22.3%

Kiniksa Pharmaceuticals International, plcKNSA

$27.48M+42.2%

Ligand PharmaceuticalsLGND

$2.15M-95.7%

Segments

By product

See full

ARQ-234 program costs$11M—

Topical roflumilast program costs$3.31M+129%

Other program costs$95K—

Other financials

Income statement

See full

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Cash flow

See full

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Valuation

See full

Market cap$3.28B+57.5%

Enterprise value$3.36B+57.0%

P/S7.9×-1.9×

Profitability

See full

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s R&D?: Arcutis Biotherapeutics, Inc. (ARQT) reported R&D of $30.63M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s R&D changed year-over-year?: Arcutis Biotherapeutics, Inc.'s R&D increased by 74.6% year-over-year, from $17.54M to $30.63M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s R&D has grown at a -14.7% compound annual growth rate (CAGR), from $145.56M to $77.05M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.